These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3206372)

  • 21. Dialysis membrane biocompatibility: effects on cellular elements.
    Coli L; De Sanctis LB; Feliciangeli G; Iannelli S; Scolari MP; Todeschini P; Tumietto F; Costigliola P; Chiodo F
    Nephrol Dial Transplant; 1995; 10 Suppl 10():27-32. PubMed ID: 8825429
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical characterization of Dicea a new cellulose membrane for haemodialysis.
    Hoenich NA; Woffindin C; Cox PJ; Goldfinch M; Roberts SJ
    Clin Nephrol; 1997 Oct; 48(4):253-9. PubMed ID: 9352161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [C-reactive protein (CRP) as a marker of of hemodialysis biocompatibility].
    Szepietowski T; Krajewska M
    Polim Med; 1997; 27(1-2):47-59. PubMed ID: 9380601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of hemodialysis (HD) membranes on interleukin 1-beta (IL-1 beta) production from peripheral blood mononuclear cells (PBMC).
    Momoi T; Ono M; Takagi T; Sugiura S; Ogawa H; Saito A
    Clin Nephrol; 1995 Nov; 44 Suppl 1():S24-8. PubMed ID: 8608657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biocompatibility and clinical performance of a new modified cellulose membrane.
    Bosch T; Schmidt B; Samtleben W; Gurland HJ
    Clin Nephrol; 1986; 26 Suppl 1():S22-9. PubMed ID: 3829464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A study of innate immunity in patients with end-stage renal disease: special reference to toll-like receptor-2 and -4 expression in peripheral blood monocytes of hemodialysis patients.
    Kuroki Y; Tsuchida K; Go I; Aoyama M; Naganuma T; Takemoto Y; Nakatani T
    Int J Mol Med; 2007 May; 19(5):783-90. PubMed ID: 17390084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interleukin 8 and biocompatibility of dialysis membranes.
    Niwa T; Miyazaki T; Sato M; Kambe F; Tsuzuki T; Uema K; Maeda K; Seo H
    Am J Nephrol; 1995; 15(3):181-5. PubMed ID: 7618641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of membrane composition and structure on solute removal and biocompatibility in hemodialysis.
    Clark WR; Hamburger RJ; Lysaght MJ
    Kidney Int; 1999 Dec; 56(6):2005-15. PubMed ID: 10594776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oxidant and carbonyl stress-related apoptosis in end-stage kidney disease: impact of membrane flux.
    Bordoni V; Piroddi M; Galli F; de Cal M; Bonello M; Dimitri P; Salvatori G; Ranishta R; Levin N; Tetta C; Ronco C
    Blood Purif; 2006; 24(1):149-56. PubMed ID: 16361856
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In-vivo induction of monocyte chemotactic and activating factor in patients with chronic renal failure.
    Akahoshi T; Kobayashi N; Hosaka S; Sekiyama N; Wada C; Kondo H
    Nephrol Dial Transplant; 1995 Dec; 10(12):2244-9. PubMed ID: 8808219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Evaluation of the biocompatibility of dialyzers by leukocyte kinetics and the dynamics of the blood acid-base balance].
    Iarmolinskiĭ IS; STetsiuk EA; Efimov NN; Sidorenko AM
    Urol Nefrol (Mosk); 1987; (5):43-6. PubMed ID: 3424468
    [No Abstract]   [Full Text] [Related]  

  • 32. Ultrathin silicon membranes for wearable dialysis.
    Johnson DG; Khire TS; Lyubarskaya YL; Smith KJ; Desormeaux JP; Taylor JG; Gaborski TR; Shestopalov AA; Striemer CC; McGrath JL
    Adv Chronic Kidney Dis; 2013 Nov; 20(6):508-15. PubMed ID: 24206603
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hemodialysis biocompatibility mathematical models to predict the inflammatory biomarkers released in dialysis patients based on hemodialysis membrane characteristics and clinical practices.
    Abdelrasoul A; Westphalen H; Saadati S; Shoker A
    Sci Rep; 2021 Nov; 11(1):23080. PubMed ID: 34845257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Membranes for blood purification: state of the art and new developments.
    Strathmann H; Göhl H
    Contrib Nephrol; 1990; 78():119-40; discussion 140-1. PubMed ID: 2225829
    [No Abstract]   [Full Text] [Related]  

  • 35. High cut-off dialysis membranes: current uses and future potential.
    Gondouin B; Hutchison CA
    Adv Chronic Kidney Dis; 2011 May; 18(3):180-7. PubMed ID: 21531324
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of dialysis membranes on outcomes in acute renal failure: a meta-analysis.
    Subramanian S; Venkataraman R; Kellum JA
    Kidney Int; 2002 Nov; 62(5):1819-23. PubMed ID: 12371984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure of dialysis membranes and long-term clinical outcome.
    Bonomini V; Coli L; Scolari MP; Stefoni S
    Am J Nephrol; 1995; 15(6):455-62. PubMed ID: 8546165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute renal failure: role of dialysis membrane biocompatibility.
    Pascual M; Swinford RD; Tolkoff-Rubin N
    Annu Rev Med; 1997; 48():467-76. PubMed ID: 9046977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platelet activation and PDGF-AB release during dialysis.
    Donati G; Cianciolo G; D'Addio F; Colì L; La Manna G; Feliciangeli G; Stefoni S
    Int J Artif Organs; 2002 Dec; 25(12):1128-36. PubMed ID: 12518957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Altered interleukin-1 production in patients undergoing hemodialysis.
    Blumenstein M; Schmidt B; Ward RA; Ziegler-Heitbrock HW; Gurland HJ
    Nephron; 1988; 50(4):277-81. PubMed ID: 3266310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.